Emerson Clinical Research Institute | Falls Church, VA

Research site

(Unclaimed)

Location

410 S. Washington Street, Falls Church, Virginia, United States of America

Site insights

Top conditions

Top treatments

APL-2

Bimatoprost

Netarsudil

PVP

CBT-001

Povidone

Elamipretide

BI 1584862

Timolol Maleate

Iodine

Parent organization

This site is a part of Emerson Clinical Research Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 18 total trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling

Wet Age Related Macular Degeneration

wAMD

Drug: Aflibercept (2.0 mg)

Drug: EYP-1901

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle i...

Enrolling

Pterygium

Drug: CBT-001

Drug: Vehicle

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

This study is open to adults aged 55 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study i...

Enrolling

Geographic Atrophy

Drug: BI 1584862

Drug: Placebo-matching BI 1584862

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalm...

Active, not recruiting

Glaucoma

Ocular Hypertension

Drug: Rhopressa®

Drug: T4090 0.3%

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR (Maia)

This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hyper...

Invitation-only

Open-Angle Glaucoma

Ocular Hypertension

Drug: Bimatoprost SR

Other: Standard of Care

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular deg...

Enrolling

Age Related Macular Degeneration (ARMD)

Drug: Elamipretide

Drug: Placebo